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Abstract
Latin America includes Mexico, the islands of the Caribbean and Central and South 
America, which possess a rich cultural and natural heritage. A narrative literature review 
was made to determine epidemiological hepatitis B and C profiles in high risk groups 
in Latin America, such as, drug users, hemophiliacs, and chronic kidney disease (CKD), 
human immunodeficiency virus (HIV) infected individuals. Using data from international 
databases that disseminate published quality studies. All studies with desired information 
regarding site and study population were included. It was observed that HBV prevalence 
diminished in several groups, probably due to implementation of HBV vaccination in var-
ious Latin America Countries (LACs). On the other hand, HCV prevalence is high among 
high risk groups compared to general population, but different values were observed in 
LAC, probably due to different access to education programs, assays evaluated, popula-
tion size and type of recruitment. Due to chronicity of HBV and HCV, it is important to 
increase access to diagnosis, HBV vaccination and implementation of education programs 
to high risk groups to diminish burden of these infections.
Keywords: HBV, HCV, prevalence, HIV, chronic kidney disease, coagulopathy, illicit 
substance abuse
1. Introduction
The Latin American and Caribbean region encloses the Spanish, Portuguese and French-
speaking countries of the American continent and covers almost 22,000,000 km2. It includes 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, El Salvador, Ecuador, Guatemala, 
Haiti, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Dominican Republic, Uruguay 
and Venezuela, which possess a rich cultural and natural heritage [1].
Clinical manifestation of hepatitis B and C virus infection varies in both acute and chronic 
disease. HBV acute phase could be subclinical or anicteric hepatitis to icteric hepatitis and 
in some cases fulminant hepatitis. Acute Hepatitis C is often asymptomatic and leads to 
chronic infection in about 75% of cases. During the chronic phase, manifestations range from 
an asymptomatic carrier state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. 
Extrahepatic manifestations can occur in both acute and chronic infection. Pathophysiology is 
based on the inflammatory response to the virus that replicates in the hepatocyte [2–4].
Viral hepatitis is an important public health issue over the world, but there is still some gaps 
regarding the prevalence of these viruses in Latin America. Hepatitis B virus (HBV) infection 
has a heterogeneous distribution in Latin America and it is estimated at least 7–12 million 
people infected by virus [5]. Most of Latin American countries presented low seroprevalence 
(less than 2% of HBsAg positivity), including Mexico, Honduras, Nicaragua, Costa Rica, 
Panama, Cuba, Paraguay, Uruguay, Chile, Argentina, Peru and North Colombia. Intermediate 
seroprevalence (2.0–8.0% of HBsAg) are observed in Central America (Guatemala, Belize, El 
Salvador, Honduras, Haiti the Dominican Republic and Puerto Rico), Ecuador, Venezuela, 
Guyana, Surinam, French Guyana and South of Brazil. High seroprevalence (>8% of HBsAg 
presence) are observed in Peru, South Colombia, Northern Bolivia and Northern Brazil; how-
ever, these reports are primarily estimates [6–9].
Hepatitis C virus (HCV) infection prevalence varies from 1.2 to 1.6% in Peru, Mexico, 
Venezuela, Argentina and Brazil where almost 80% were viremic [9]. According the same 
study, genotype 1 was the most frequent detected, but genotype 1b was the most prevalent 
in all countries except in Peru where genotype 1a was the highest prevalent. Díez-Padrisa 
et al. [7] reported that Grenada, Bolivia, Haiti, Trinidad and Tobago and El Salvador have the 
highest prevalence (≥2.5%) in Latin America.
Epidemiological studies to determine HBV and HCV prevalence are important, principally 
among high risk population, such as human immunodeficiency virus (HIV) infected subjects, 
drug users, hemophiliacs and chronic kidney patients. HIV individuals coinfected with HBV 
or HCV could present clinical complications of liver disease and increased risk of developing 
cirrhosis. Individuals who are drug and alcohol abusers are at risk of becoming infected with 
HBV or HCV due to unprotected sexual practices that are common to these users besides 
the sharing of needles and syringes [10]. Chronic kidney disease (CKD) and coagulopathy 
patients are often exposed to blood, such as during hemodialysis or blood components trans-
fusion where the risk of contracting viral infections is also very high [11].
Knowing the scenario of HBV and HCV infection in Latin American countries (LAC) is 
important to raise awareness among the population and health professionals, strengthening 
preventive measures mainly among the high-risk population, increasing access to diagnosis, 
improving the attendance of the diagnosed cases, treatment and monitoring [7]. In this chap-
ter, a narrative literature review was undertaken to give information for developing policies 
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and evidence-based care. This type of review gives comprehensive background for under-
standing current knowledge and highlighting the significance of new research in this area.
2. Methodology
A narrative review of the literature was done using SCIELO, LILACS and MEDLINE® data-
base searches in an iterative manner during December to April 2018 to retrieve articles related 
to current and historical epidemiological profile of hepatitis B and C in the countries of Latin 
America and the Caribbean.
Search terms included “hepatitis B,” “hepatitis C,” “HIV,” “illicit substance,” “drug user”, “CKD”, 
“dialysis”, “coagulopathy”, “prevalence”, “epidemiology”, “Latin America”. The reference lists 
of each article found were also reviewed in detail to find additional articles.
All authors independently read each article in full text, evaluated the relevance and quality of 
retrieved articles to include the data, and recorded the main findings of each study to include 
the relevant articles in Table 1. Primary and secondary studies were included in the review, 
but duplicate studies were removed.
3. Results and discussion
3.1. Hepatitis B and C prevalence in patients infected by HIV
HIV infection can increase clinical complications of liver disease associated to HBV and HCV, 
such as increasing the risk of developing cirrhosis up to five times in those co-infected with 
HIV/HCV [12]. With antiretroviral therapy and a significant increase in the life expectancy of 
people living with HIV, liver disease in patients with HCV and/or HBV infection has become 
the leading cause of non-AIDS-related deaths in this population.
In Latin America and the Caribbean, the prevalence of HBV and HCV in people living with 
HIV is quite variable. Moreover, few data are available, unlike data for Europe and the United 
States [12]. Over the world, 10% of people infected with HIV are also coinfected with HBV 
[13], since both viruses has the parenteral and sexual pathways as a route of infection, coinfec-
tion of these two viruses are common [14].
According Tengan et al. [15], estimated prevalence of HBsAg in LAC ranged from 2.0% (95% 
CI 1.0–5.0%) to 15.0% (95% CI 9.0–24.0%) and pooled prevalence was 7.0% (95% CI 7.0–7.0%). 
They also observed a drop in HBsAg prevalence from 8.0% (95% CI 8.0–9.0%) in the 12 studies 
published from 1999 to 2006 to 6.0% (95% CI 5.0–6.0%) in 16 studies published from 2007 to 
2016. The decrease in HBsAg prevalence could be related to implementation of vaccination 
against hepatitis B.
In Brazil, HBsAg prevalence in HIV infected individuals ranges from 1.9 to 10.3% according 
geographical regions [15–18]. Tengan et al. [15] reported HBsAg prevalence in HIV of 3.3% in 
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Authors Country Year 
study
Type of study Methodology Key findings Comments, if any
Alonso et al. [38] Latin 
America and 
Caribe
2015 Secondary study/
analyze database/
systematic review
53 studies included both 
genders
Injecting drug users, HBV, HCV, 
Latin America and prevalence
Degenhardt et al. 
[28]
Latin 
America and
2017 Secondary study/
analyze database/
systematic review
976 studies/individuals 
15–64 years, both 
genders
Injecting drug users, HBV, HCV, 
Latin America and prevalence
Global study
Bautista-
Amorocho et al. 
[14]
Colombia 2014 Primary study 275 individuals, 
2009–2010, both genders 
s
HIV, HBV, HCV, Latin America 
and prevalence
Mejia et al. [50] Colombia 2004 Conference No information Injecting drug users, HBV, Latin 
America and prevalence
Summaries of a conference
Weissenbacher 
et al. [45]
Argentina 2003 Primary study 174 individuals, average 
of 30 years and both 
genders
Injecting drug users, HBV, HCV, 
Latin America and prevalence
Sheehan et al. [40] Argentina 2012 Primary study 205 individuals, age 
18–65 years, 2005–2006 
and both genders
Injecting drug users, HBV, HCV, 
Latin America and prevalence
Caiaffa et al. [46] Brazil 2006 Primary study 1144 individuals, 
1998–2001 and both 
genders
Injecting drug users, HBV, HCV, 
Latin America and prevalence
Osimani et al. [43] Uruguay 2003 Secondary study/
analyze database/
systematic review
367 individuals, both 
genders and aging over 
18 years
Users of illicit drugs, HBV, HCV, 
Latin America and prevalence
Monsalvand 
Castillo et al. [51]
Venezuela 2007 Primary study 197 individuals of both 
genders
Risk population, HBV, HCV, 
Latin America and prevalence
Reyes et al. [47] Porto Rico 2006 Primary study 400 individuals of both 
genders
Injecting drug users, HBV, HCV, 
Latin America and prevalence
Lopes et al. [53] Brazil 2009 Primary study 691 individuals, both 
genders and 2005–2006
Injecting drug users, HBV, HCV, 
Latin America and prevalence
Drug-treatment centers
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Authors Country Year 
study
Type of study Methodology Key findings Comments, if any
Germano et al. 
[42]
Brazil 2010 Primary study 750 individuals and both 
genders,
Risk population, HBV, HCV, 
Latin America and prevalence
Voluntary Counseling and Testing 
Center
Oliveira et al. [30] Brazil 1999 Primary study 102 individuals and both 
genders
Users of illicit drugs, HBV, HCV, 
Latin America and prevalence
Oliveira-Filho 
et al. [41]
Brazil 2013 Primary study 384 individuals and both 
genders
Risk population, of illicit drugs, 
HBV, HCV, Latin America and 
prevalence
Pazeto et al. [30] Brazil 2012 Primary study Individuals and both 
genders
Risk population, HBV, HCV, 
Latin America and prevalence
Alcoholic individuals
Cortês et al. [37] Brazil 2013 Primary study 90 individuals and both 
genders
Risk population, HBV, HCV, 
Latin America and prevalence
Alcoholic individuals
Santos-Cruz et al. 
[36]
Brazil 2013 Primary study 160 individuals, ages 
18–24, both genders from 
2010 to 2011
Users of illicit drugs, HBV, HCV, 
Latin America and prevalence
Ferreira et al. [79] Brazil 2009 Primary study 1095 individuals and 
both genders
Hemodialysis, HBV, HCV, Latin 
America and prevalence
Dialysis units
Marchesini et al. 
[32]
Brazil 2007 Primary study 205 individuals and both 
genders
Users of illicit drugs, HBV, HCV, 
Latin America and prevalence
Public health clinics.
Matos et al. [33] Brazil 2013 Primary study 149 individuals and both 
genders
Users of illicit drugs, HBV, HCV, 
Latin America and prevalence
Novaes et al. [32] Brazil 2009 Primary study, 
transversal
314 individuals and male 
gender
Users of illicit drugs, HBV, HCV, 
Latin America and prevalence
Andrade et al. 
[29]
Brazil 2017 Primary study, 
transversal
66 individuals, 28.4 years 
and most were male
Users of illicit drugs, HBV, HCV, 
Latin America and prevalence
Frost et al. [48] Mexico 2006 Primary study 200 individuals and year 
of 2005
Users of illicit drugs, HBV, HCV, 
Latin America and prevalence
Valtuille et al. [61] Argentina 2002 Primary study 1994–2000 Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
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Authors Country Year 
study
Type of study Methodology Key findings Comments, if any
Marinovich et al. 
[62]
Argentina 2012 Primary study 13,466 with mean age of 
60.4 years
Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Méndez-Chacon 
et al. [59]
Peru 2005 Primary study 128 patients and year 
of 2000
Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Pujol et al. [60] Venezuela 1996 Primary study 227 patients Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
spread in hemodialysis
Gonzalez et al. 
[65]
Chile 2000 Primary study Year of 1995 Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Santana et al. [65] Cuba 2009 Multi-center analysis Year of 1995 Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Cabezas et al. [67] Cuba 2010 Primary study Year of 1995 Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence and 
prevalence
Spread in hemodialysis
López et al. [59] Uruguay 2005 Cross-sectional 
study
409 patients Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Multi-transfused patients
González Michaca 
et al. [68]
Uruguay 2000 Cross-sectional 
study
235 patients Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Méndez-Sanchez 
et al. [69]
Mexico 2004 Primary study 149 patients Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Paniagua et al. 
[77]
Mexico 2010 Primary study, 
cross-sectional study
368 patients and mean 
age of 52 years
Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
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Authors Country Year 
study
Type of study Methodology Key findings Comments, if any
Oliveira-Penido 
et al. [75]
Mexico 2008 Primary study 884 patients, between 41 
and 60 years old and the 
majority male
Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Leão et al. [76] Brazil 2010 Primary study, 
cross-sectional study
236 patients and year 
of 1995
Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Guimarães et al. 
[78]
Brazil 2017 Primary study, 
cross-sectional study
181 patients and the 
majority male
Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
de Jesus et al. [74] Brazil 2013 Primary study 798 patients Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Ribeiro Barbosa 
et al. [17]
Brazil 2017 Primary study, 
cross-sectional study
798 patients Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Callegaro et al. 
[72]
Brazil 2006 Primary study 798 patients and year of 
2000–2002
Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Carrilho et al. [80] Brazil 2004 Primary study 813 patients, 149 
hemodialysis workers 
and 772 healthy controls
Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Ferreira et al. [81] Brazil 2006 Primary study 1095 patients Hemodialysis, chronic kidney 
disease, HBV, HCV, Latin 
America and prevalence
Spread in hemodialysis
Tengan et al. [12] Latin 
American 
countries
2016 Systematic review 37 studies HIV, HBV, HCV, Latin America 
and prevalence
People living with HIV/AIDS
Greer et al. [19] Brazil 2017 Primary study 1241 HIV positive and 
1232 HIV negative 
subjects
HIV, HBV, HCV, Latin America 
and prevalence
Flores et al. [16] Brazil 2017 Primary study, 
cross-sectional study
409 individuals HIV, HBV, HCV, Latin America 
and prevalence
HCV+ our HBV+ individuals
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Authors Country Year 
study
Type of study Methodology Key findings Comments, if any
Toscano and 
Corrêa [18]
Brazil 2017 Primary study 2242 individuals HIV, HBV, HCV, Latin America 
and prevalence
People living with HIV/AIDS
Oliveira et al. [21] Brazil 2016 Primary study 505 individuals HIV, HBV, HCV, Latin America 
and prevalence
Freitas et al. [24] Brazil 2004 Primary study 848 individuals HIV, HBV, HCV, Latin America 
and prevalence
People living with HIV/AIDS
Brandão et al. [25] Brazil 2015 Primary study 495 individuals HIV, HBV, HCV, Latin America 
and prevalence
People living with HIV/AIDS
Tizzot et al. [26] Brazil 2016 Primary study 303 individuals and 
mean age 41.2 years
HIV, HBV, HCV, Latin America 
and prevalence
People living with HIV/AIDS
Bautista-
Amorocho et al. 
[20]
Colombia 2014 Primary study 275 individuals and year 
of 2009–2010
HIV, HBV, HCV, Latin America 
and prevalence
People living with HIV/AIDS
Quarleri et al. [22] Argentina 2007 Primary study 593 individuals HIV, HBV, HCV, Latin America 
and prevalence
People living with HIV/AIDS
Ballester et al. [95] Cuba 2005 Primary study 318 individuals Hemophilia, HBV, HCV, Latin 
America and prevalence
Multi-transfused patients
Beltrân et al. [71] Colombia 2005 Primary study 500 individuals Hemophilia, HBV, HCV, Latin 
America and prevalence
Groups: hemophilia, hemodialysis, 
acute bleeding, ontological illnesses 
and sickle cell disease or thalassemia
Laguna-Torres 
et al. [97]
Peru 2005 Cross-sectional 
multi-center study
351 patients and year of 
2003–2004
Hemophilia, HBV, HCV, Latin 
America and prevalence
Multi-transfused patients
Vinelli and 
Lorenzana [94]
Honduras 2005 Cross-sectional 
study
502 patients and year of 
2002–2005
Hemophilia, HBV, HCV, Latin 
America and prevalence
Multi-transfused patients
Remesar et al. 
[100]
Argentina 2005 Multi-center, cross-
sectional study
504 patients Hemophilia, HBV, HCV, Latin 
America and prevalence
Multi-transfused patients
Ferreira et al. [98] Brazil 2014 Secondary study, 
analyze database
9122 patients Hemophilia, HBV, HCV, Latin 
America and prevalence
Patients with hemophilia A
Table 1. Main characteristics of studies included in the review according country and type of individuals.
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Colombia, 3.1% in Venezuela, 6.1–8.5% in Chile, 3.3–14.5% in Argentina, 5.1–10.3% in Cuba. 
Occult hepatitis B infection (OBI) has been reported in 3.8% of HIV infected individuals from 
Central West region in Brazil and 12% of Colombian HIV people [20, 21]. HBV genotype A 
was the most detected in studies from Brazil and Argentina while genotype F was most found 
in Colombia [17, 19–22].
All over the world, HIV/HCV coinfection is reported in 4% of HIV-infected people and prob-
ability of HCV infection is six times higher in people living with HIV than in the general 
population [23]. Recently, a systematic review reported prevalence of HIV/HCV co-infection 
in Latin America of 8% varying from 5 to almost 50% according countries [23]. In LAC, the 
estimated seroprevalence of HCV infection varied from 0.8 to 58.5% (mean 17.37; median 
10.91), with the highest in Argentina (58.5%) and Brazil (53.5%) and the lowest in Venezuela 
(0.7%) and Colombia (0.8%) [12].
The differences in HCV prevalence observed in LAC were probably due to difference in 
assays used and characteristics of the population included. In addition, it was observed that 
HCV prevalence is higher in HIV infected individuals compared to general population in 
Latin America countries [12].
Recent studies found anti-HCV prevalence in HIV infected individuals of 1.3% in Northeast 
Brazil, 4.6% in Southeast Brazil, 12.9% in South Brazil, 6.9–9.7% in Midwest Brazil [16, 17, 
24–26]. In all of these studies, HCV genotype 1 was the most prevalent.
This high rate of coinfection among these viruses is probably due to the common transmission 
of these infections, especially among high risk individuals, such as injecting drug users (IDU) 
living with HIV. Health preventive measures for reducing HBV and HCV infection in these 
individuals could reduce the prevalence of hepatitis viruses in Latin America region.
3.2. HBV and HCV infection in illicit substance users
According to United Nations Office on Drugs and Crime (UNODC) [27], around 5% of the 
global adult population used illicit substance at least once in 2015 and 0.6% of global adult 
population suffer from drug use disorders [27]. The consumption of psychoactive substances 
is related to risks and damages of great social magnitude: unprotected sexual practices, shar-
ing of syringes and needles, as well as exposure to sexually transmitted and parenteral infec-
tions, such as HBV [10]. Worldwide prevalence of HBV infection among injecting drug users 
(IDU) is estimated at 7.4%, suggesting that 880,000 IDU are infected with HBV [27].
In Latin America, the most consumed illicit substance by individuals at drug treatment is 
Cannabis (around 45%), followed by Cocaine (almost 40%). Recent systematic review demon-
strated that HBsAg prevalence varies from 2 to 10% among people who inject drug (PWID) 
in Latin America countries [28]. In this review, studies published from 2011 to 2017 were 
included and most of PWID were young (aging less than 25 years), had history of arrest and 
incarceration, and use opioid.
Most of prevalence studies of HBV in illicit substance users (ISU) in Latin America were con-
ducted in Brazil, followed by Argentina, Colombia, Mexico and Uruguay. In Northern Brazil, 
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HBV prevalence (anti-HBc positivity) was 36.7% in ISU, genotypes A, D and F were found 
and risk factors were: (i) male gender, (ii) age above 35 years, (iii) anti-HIV positivity, (iv) 
tattoos, (v) the use of injected drugs, (vi) the use of illicit drugs for more than 3 years, (vii) 
sexual relations without protection, (viii) sexual relations with another DU, and (ix) more 
than 10 sexual partners in the past 24 months [29]. In Southeast Brazil, anti-HBc prevalence 
around 55% was found among IDU in 1999 and IDU living with HIV in 2007. It is important to 
observe that HBsAg prevalence drops from 7.8 to 3.4% in this region what could be the result 
of vaccination campaigns [30–32]. Occult HBV infection (OBI) of 12.7% was also documented 
in IDU from Central West region of Brazil demonstrating a high prevalence of OBI in this 
population [33].
Among non-injecting drug users (NIDU) (crack, alcohol, marijuana, cocaine), HBsAg preva-
lence varies from 0.1 to 6.2% according geographical regions in Brazil showing a low risk in 
this group compared to IDU [34–37].
HCV prevalence varies among ISU in Latin America. Degenhardt et al. [28] estimates preva-
lences less than 40% and higher than 80% among IDU in Latin America. A recent review 
included studies from 2000 to 2013 conducted in Argentina, Brazil, Colombia, Dominican 
Republic, Mexico, Panama, Peru, Puerto Rico, Uruguay and Venezuela [38]. Anti-HCV preva-
lence in ISU was below 7% in the majority of studies included in this review, but anti-HCV 
rates from 30 to 67% were found in ISU in Argentina and Brazil [39–41].
In NIDU, anti-HCV ranged from 0 to 10% with the highest values found in Brazil (8%), and 
Uruguay (10% in 2003) [42]. Studies conducted in alcohol abusers found 5.6% of anti-HCV 
in Southeast Brazil [37] and 15% in Southern Brazil [43] what could reflect the diminish in 
anti-HCV prevalence in this group. The pooled value for HCV prevalence in NIDU was 3.6% 
(95% CI 2.6–4.5%) [38].
HCV infection rate for IDU varied considerably between and within countries. The high-
est values were reported in Argentina (55% in 2001) [44], Brazil (53% in 1998, 46% in 2001) 
[45], Puerto Rico (89% in 2006) [46] and Mexico (Ciudad Juarez and Tijuana) (96% in 2005) 
[47]. Studies in Colombia (Bogota) found anti-HCV prevalence of 0 and 1.7% in IDU [48, 49]. 
Pooled regional anti-HCV prevalence among IDU was 49% (95% CI 22.6–76.3%) with signifi-
cant heterogeneity among studies [38].
HCV current infection (both anti-HCV and HCV-RNA) varies from 0% in drug users from 
Venezuela [50] to almost 60% in IDU in North Brazil [41]. Only three studies from Brazil [41, 
51–53] determined HCV genotypes. The study from Pará found a high prevalence of genotype 
1b (42%), especially in NIDU (50%), while in the other two studies, individuals had genotype 
1a in over 60%.
3.3. Hepatitis B and C prevalence in patients with chronic kidney disease patients 
under dialysis treatment
It is well known that patients undergoing dialysis treatment are at increased risk for con-
tracting viral infections. The reasons may be their underlying impaired cellular immunity 
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and the blood exposure to infectious materials through the extracorporeal circulation for a 
prolonged period. Moreover, hemodialysis patients may require blood transfusion, frequent 
hospitalizations and surgery, which increase opportunities for nosocomial infection expo-
sure [11]. Most frequent viral infections reported hemodialysis units are HBV, HCV and HIV 
[54]. These infections influence negatively the survival of the hemodialysis patients and those 
undergoing renal transplant [55].
Worldwide, HCV prevalence among patients on hemodialysis varies from as low as 1 to up 
to 70% [56] and the dialysis-related risk of HCV infection development is estimated at 2% 
per year [54]. Anti-HCV prevalence is low in Latin America (about 1.23%) [57] and varies 
from country to country, between regions of the same country and even among hemodi-
alysis patients [58]. High anti-HCV prevalence was found in hemodialysis patients in Peru 
(59%) and from them, 4.5% had mixed infection with hepatitis B (HBsAg positive) [59]. In 
Venezuela, a study conducted in four hemodialysis units found 71% of anti-HCV and 25% of 
HBsAg among hemodialysis patients [60].
In Argentina, a study demonstrated a drop in anti-HCV prevalence in a same hemodialysis 
unit showing prevalence of 41.5% in 1994; 26.9% in 1996; 12% in 1998 and 8.5% in 2000 [61]. 
According to the Chronic Dialysis Registry of Argentina, anti-HCV prevalence decreased 
from 2% in 2004 to 1% in 2011 and global HCV prevalence was 4.9% in 2011 [62, 63].
In Chile, anti-HCV prevalence varied from 30% in hemodialysis patients at 1993 to 13% 2 
years later [64, 65]. In Cuba, despite the implementation of anti-HCV screening in 1995, high 
anti-HCV positivity was found in hemodialysis patients in 2009 (76%) and 2010 (18.8%) [66, 
67]. In Mexico, anti-HCV prevalence of 10.2% was observed in CKD patients and 12.7% in 
those at hemodialysis [68]. Years later, a study showed that among 149 patients in hemodi-
alysis, 6.7% presented anti-HCV antibodies and from them, 5% presented HCV RNA [69]. 
Anti-HCV prevalence of 6.3, 6.5, 59% in hemodialysis patients from Uruguay, Colombia, Peru 
[59, 70, 71].
In Brazil, some studies have been performed to evaluate HCV prevalence in different hemo-
dialysis units. In 2006, among 70 patients of the south region undergoing hemodialysis, seven 
(10%) presented HCV infection [72]. Still in 2006, but in Salvador city (Northeast Brazil), the 
anti-HCV prevalence among hemodialysis patients was 10.5% with detectable HCV RNA in 
73.6% of them. In this study, the most frequent HCV genotype was genotype 1 followed by 
genotypes 3 and 2 [73]. In North region, anti-HCV prevalences from 4 to 14% were found in 
7 dialysis center in Para State in 2013. In this study, HCV RNA was detected in 5.3% of the 
patients and genotype 1 was the most frequent, followed by genotypes 2 and 3 [74]. Recently, 
Barbosa-Ribeiro et al. [17] found 12.6% of anti-HCV prevalence in Hemodialysis patients at 
Northeast Brazil. In Southeast region, anti-HCV prevalence of 13 and 14.8% was found in 2008 
and 2010 years [75, 76].
HBV prevalence varies in CKD patients in Latin America. In Mexico [77] found 7.1% of 
HBsAg prevalence in 10 hemodialysis units at 2010 and two of them were co-infected with 
HCV (0.5%) [77]. In Uruguay, HBsAg prevalence of 1% was found in hemodialysis patients 
probably due to mandatory screening of blood donors and patients for HBsAg since 1981 [71]. 
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In Brazil, prevalence of HBsAg of 0, 2.4, 7, 10, 34.1% were reported in hemodialysis center in 
Southeast, Central, Northeast, South and Midwest regions of Brazil [78–82]. HBsAg preva-
lence of 4.5, 25, 1.4% was found in hemodialysis patients in Peru, Venezuela, Cuba [59, 67].
Among patients undergoing hemodialysis, it is relatively common to observe occult hepatitis 
B cases due to vial of transmission and prolonged vascular access [83]. In Brazil, prevalence 
of OBI of 1.5, 3 and 15% was found in Northeast and Southeast region of Brazil [83–85]. HBV 
genotype A was the most prevalent in these studies.
3.4. HBV and HCV infection among coagulopathy patients
Hereditary coagulopathies are hemorrhagic diseases resulting from deficiency of one or more 
plasma coagulation proteins, implying a reduction in the formation of thrombin which is a 
key factor for blood clotting. Among hereditary hemorrhagic disorders, hemophilia (type A 
and B) and von Willebrand’s disease (VWD) are the most common [86]. Hemophilia A and B 
are X-linked hemorrhagic disorders caused by mutations in the factor VIII and factor IX genes, 
affecting almost exclusively male individuals. Both factors play a role in the intrinsic pathway 
of blood clotting and the affected individuals present severe, moderate and mild forms of 
disease defined by plasma coagulation factor levels [87]. While VWD is caused by a decreased 
or dysfunction of the protein called Von Willebrand Factor (VWF) and affects both genders. 
The diversity of mutations leads to the appearance of several clinical manifestations, manifest-
ing with platelet dysfunction associated with the decrease of serum levels of factor VIII [88].
Worldwide, it is estimated that hemophilia affects 1 in 5000 newborns while VWD reaches 
from 0.8 to 2% of the population. According to the 2015 global annual report of the World 
Federation of Hemophilia, which included data from more than 304,000 people with heredi-
tary coagulopathy from 111 countries, 49.7% of the cases were from hemophilia A, 9.9% from 
hemophilia B, 24.6% of DVW and 13.9% of other coagulopathies [86].
The treatment of coagulopathies is based on the replacement of the deficient coagulation 
factor, when there are hemorrhagic manifestations or as primary prophylaxis. This therapy 
increases the survival of these patients and their success in preventing the different hemor-
rhagic manifestations [89, 90]. On the other hand, due to multiple blood transfusions and use 
of cryoprecipitate, elaborated from a pool of frozen human plasma, these individuals are at 
risk for transmission of infectious agents, such as hepatitis B and C viruses [91, 92].
Most of viral infections occurred before 1985, when inactivation techniques were introduced 
in clotting factor concentrates. Thus, countries in Latin America, as well as other regions of 
the world, suffer the impact of these viral infections, which have evolved into chronic cases 
of the disease.
HBsAg prevalences were 2.4, 6, 24, 33.3 and 42% in coagulopathy patients from Mexico, 
Honduras, Cuba, Colombia, Peru [93–97]. In Brazil, it was possible to observe a significant 
decrease in the prevalence of HBsAg over the years, being 2.3% in 2007 and 1.0% in 2012 [98].
Regarding anti-HCV prevalence in coagulopathy patients, a universal screening in 1995 
identified 51.6% of anti-HCV in hemophiliac patients from Cuba [95]. In 2007 to 2010, anti-
HCV prevalence was 39.03% in this group in Cuba [99]. While in Colombia, patients from the 
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cities of Bogotá and Medellin in 2003 presented 32.2% of anti-HCV [74]. In Peru, a study with 
multi-transfused patients from the seven largest hospitals in the country revealed 56.6% of 
anti-HCV prevalence [97]. In Honduras, 8 hospitals in the cities of Tegucigalpa and San Pedro 
Sula identified anti-HCV prevalence of 26.9% [94]. In Mexico, 46.3% of anti-HCV prevalence 
was found in hemophiliacs at 2008 [93]. In Argentina, 42.7% of anti-HCV positivity was found 
in hemophiliacs from 2002 to 2004 [100]. As the same was found for HBV, Ferreira et al. [98] 
observed a decrease in anti-HCV prevalence from 24.2% in 2007 to 4.7% in 2012. However, 
recent study in coagulopathy patients from Northeast Brazil found 47% of anti-HCV preva-
lence [17].
4. Conclusion(s)
In Latin America countries, HBV and HCV infection are still great public health problem in 
individuals infected by HIV, CKD patients, coagulopathy patients, illicit substance abusers. 
Prevalences of these infections are higher in these individuals compared to general popula-
tion and different patterns of epidemiology were found between and within countries prob-
ably due to differences in access to diagnosis and treatment in these regions. A fall in the 
prevalence of HBV and HCV infection has been observed in these groups due to HBV immu-
nization and HCV screening especially among CKD and coagulopathy patients. However, 
outbreaks still happen in these groups showing the importance of education programs to 
prevent the transmission of these viruses.
The recommendations for each group are: among CKD and coagulopathy individuals, it is 
important to provide access to sensitive methods of diagnosis, screening of blood products 
and equipment and HBV vaccination. Among ISUs and HIV infected individuals, it is impor-
tant to provide access to diagnosis, increase prevention and education campaigns to reduce 
the risk of acquiring HBV and HCV due to risky sexual behavior or sharing of needles and 
syringes. Vaccination against HBV should also be a priority in these groups. All these recom-
mendations must be made in all countries of Latin America since epidemiological differences 
between HBV and HCV infection among countries is based on the different investments made 
in health, especially those related to diagnosis and prevention.
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